Nisarg Patel

@nxpatel

Resident surgeon-scientist , . Cofounder (YC W18). Biopharma . Via , , .

SF | BOS
mit.edu/~nisargpa/
Vrijeme pridruživanja: prosinac 2012.
320 fotografija ili videozapisa Fotografije i videozapisi

Tweetovi

Blokirali ste korisnika/cu @nxpatel

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @nxpatel

  1. proslijedio/la je Tweet
    19. pro 2019.

    My latest in : Every health care debate to-date has focused on the 'freedom to choose' health insurance over issues of access and affordability. This is the wrong question. I push Presidential candidates to change that in tonight's .

    6 proslijeđenih tweetova 27 korisnika označava da im se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
    Poništi
  2. proslijedio/la je Tweet
    prije 1 sat

    Here's our latest - on genomics & immunotherapy in breast cancer for biological exploration (not clinical biomarkers!) - jointly with co-led by rising star ! Check out Dr. Keenan's tweetorial for more info👇

    1/ Why doesn’t breast cancer respond to immunotherapy? Excited to share our most recent study aimed at answering this - a genomic analysis of 62 patients with metastatic triple-negative breast cancer (mTNBC) treated with PD-1/L1 inhibitors.
    Prikaži ovu nit
    4 proslijeđena tweeta 9 korisnika označava da im se sviđa
    Poništi
  3. proslijedio/la je Tweet
    prije 19 sati

    Another addition to the many studies about benefits of Medicaid expansion. We found that low-income patients in expansion states were less likely to report access barriers as the reason for using the ER - more evidence that expansion is good for patients, docs, and govts

    Does Medicaid expansion⬆️or⬇️ED use? Perhaps a better question is did it change why low-income pt use EDs? Our take: No change in ED use, but small ⬇️in visits 2/2 perceived access barrier. With Ben Sommers
    1 proslijeđeni tweet 11 korisnika označava da im se sviđa
    Poništi
  4. proslijedio/la je Tweet
    3. velj

    Here's our latest in - jointly with the Sunyaev Lab + + - featuring 's first tweetorial 👇

    As my very first post on twitter, I am very excited to announce that our article "Identification of cancer driver genes based on nucleotide context" appeared in Nature Genetics today. Here is the link to our study:
    Prikaži ovu nit
    16 proslijeđenih tweetova 75 korisnika označava da im se sviđa
    Poništi
  5. 4. velj

    Couldn’t dream up a better metaphor for tonight’s Iowa Caucuses.

    At one Des Moines precinct tonight, an attendee brought in a concealed bottle of wine, dropped it, and it shattered everywhere
    6 korisnika označava da im se sviđa
    Poništi
  6. proslijedio/la je Tweet
    3. velj

    As my very first post on twitter, I am very excited to announce that our article "Identification of cancer driver genes based on nucleotide context" appeared in Nature Genetics today. Here is the link to our study:

    7 replies 50 proslijeđenih tweetova 163 korisnika označavaju da im se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
    Poništi
  7. proslijedio/la je Tweet
    31. sij

    Now that we're a month into 2020 and have reflected on JPM, and I are sharing some expectations and predictions for the healthcare industry.

    3 proslijeđena tweeta 8 korisnika označava da im se sviđa
    Poništi
  8. 31. sij

    Priced at $14/share—bottom of the expected range—values One Medical at ~$1.71B postmoney (not including the underwriter option).

    Pricing info for One Medical’s IPO just dropped
    3 proslijeđena tweeta 8 korisnika označava da im se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
    Poništi
  9. proslijedio/la je Tweet
    30. sij

    We have partnered w/ to provide a Methodology Toolbox for Surgical HSR. Kudos to all members involved👏

    41 proslijeđeni tweet 93 korisnika označavaju da im se sviđa
    Poništi
  10. 30. sij

    In a national drug pricing debate begging for nuance, this work and data visualization is 🔥🔥🔥

    Excited to share new work : Drug prices are a major concern for Americans. We describe the many levers policymakers have—beyond price negotiation—to reduce the cost burden on patients, while maintaining incentives for the innovation society needs.
    Prikaži ovu nit
    1 reply 1 proslijeđeni tweet 6 korisnika označava da im se sviđa
    Poništi
  11. proslijedio/la je Tweet
    28. sij

    With the IPO this week, I dove into One Medical's S-1, including: -Is its subscription biz worth the SaaS multiple valuation? -Do the unit economics show room for company growth? (feat. pearls) -Will it take on incumbent health system monopolies?

    6 replies 16 proslijeđenih tweetova 50 korisnika označava da im se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
    Poništi
  12. 28. sij

    With the IPO this week, I dove into One Medical's S-1, including: -Is its subscription biz worth the SaaS multiple valuation? -Do the unit economics show room for company growth? (feat. pearls) -Will it take on incumbent health system monopolies?

    6 replies 16 proslijeđenih tweetova 50 korisnika označava da im se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
    Poništi
  13. 27. sij

    Hands down one of my favorite courses from Harvard, check it out!

    Excited to announce a new version of our course at Harvard, BMI704: Data Science for Medical Decision Making, and to be teaching with . We'll release lectures, data, and an interactive text of data science methods at link below. Sched + Readings:
    5 korisnika označava da im se sviđa
    Poništi
  14. proslijedio/la je Tweet
    24. sij

    Thoughts are with the family of the late who just passed. He inspired many to think about “disruptive innovation,” but his most important contribution in my view was this gem on measuring one’s life.

    5 replies 11 proslijeđenih tweetova 55 korisnika označava da im se sviđa
    Poništi
  15. 22. sij

    This is obviously because the foot was optional at HMS.

    TIL that there is an anatomical structure in the foot named the MASTER KNOT OF HENRY and I am so sad I never knew this before
    8 korisnika označava da im se sviđa
    Poništi
  16. 21. sij

    Hard data illustrating the fallacy of health plan 'choice', as I wrote above.

    Health Insurance Churn in the US Is a Nightmare
    3 korisnika označavaju da im se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
    Poništi
  17. proslijedio/la je Tweet
    20. sij

    I am contemplating a curriculum on deep learning in computational biology. What papers would you suggest? I'll include some obvious ones that spring to mind below. Please RT!

    25 replies 106 proslijeđenih tweetova 287 korisnika označava da im se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
    Poništi
  18. 14. sij

    Always read and Zeke Emanuel: updated jobs data since my piece above.

    The downside of strong growth in health care jobs: higher costs via
    2 korisnika označavaju da im se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
    Poništi
  19. proslijedio/la je Tweet
    13. sij

    Looking to hire a VP of Product to lead the entire data products portfolio . Team of 20 incl 5 product verticals / directors, seriously awesome heads of data sci / design / eng, & some of the most impactful problems in healthcare/oncology. Send any and all leads!

    1 reply 5 proslijeđenih tweetova 16 korisnika označava da im se sviđa
    Prikaži ovu nit
    Prikaži ovu nit
    Poništi
  20. 13. sij

    Allogeneic CARs are hot at

    12 korisnika označava da im se sviđa
    Poništi
  21. 13. sij

    At ? Come by the office at 12pm today to chat with a group of YC health tech companies!

    1 proslijeđeni tweet 3 korisnika označavaju da im se sviđa
    Poništi

@nxpatel još nije objavio nijedan Tweet.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·